Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease (THINK)

July 31, 2026 updated by: University Hospital, Tours

Intensification of Blood Pressure Lowering Therapeutics Based on Diuretics Versus Usual Management for Uncontrolled Hypertension IN Patients With Moderate to Severe Chronic Kidney Disease: an Open Label, a Cluster Randomized Controlled, Phase 3 Trial

Chronic kidney disease (CKD) is a major public health issue worldwide. Hypertension is the first risk factor in patients with CKD for mortality, cardiovascular disease and end-stage renal disease. It's now well established that lowering blood pressure (BP) reduces renal and cardiovascular complications in this high-risk population. In the general population, in addition to lifestyle interventions, the strategy to initiate and escalate a BP-lowering drug treatment is well described. The drug therapies recommended to achieve optimal BP control in the general population are the following: blockers of the renin-angiotensin system (angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARB)), diuretics (thiazides and thiazide-like diuretics), and calcium channel blockers. For patients with CKD, the guidelines advise to start the BP-lowering agent with ACEi or ARB, but then, there is no strong evidence to support the preferential use of any particular agent in controlling BP and the results of clinical trials are discordant. In the NephroTest cohort, a French cohort of patients with CKD stage 1 to 5, among 2015 patients, 1782 had hypertension, only 54% had a diuretic and 44% had uncontrolled hypertension. In this cohort, extracellular fluid (ECF) overload was an independent determinant of hypertension, uncontrolled hypertension and apparent treatment resistant hypertension. In the same cohort, ECF overload was independently associated with end-stage kidney disease and death. Our hypothesis is that patients with CKD and uncontrolled hypertension are fluid overloaded and that the second line of treatment after an ACEi or an ARB should be a diuretic. We hypothesize that a specific algorithm to lower BP in patients with moderate to severe CKD based on diuretics will be more effective in term of cardiovascular event, mortality and evolution to end-stage kidney disease as compared to standard of care.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
720

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • France
      • Angers, France, 49933
        • Recruiting
        • Department of Nephrology, University Hospital of Angers
        • Contact:
          • Martin PLANCHAIS, MD
        • Principal Investigator:
          • Martin PLANCHAIS, MD
      • Bordeaux, France, 33000
        • Recruiting
        • Department of Nephrology, University Hospital of Bordeaux
        • Contact:
          • Pierre PFIRMANN, MD-PhD
        • Principal Investigator:
          • Pierre PFIRMANN, MD-PhD
      • Brest, France, 29200
        • Recruiting
        • Department of Nephrology, University Hospital of Brest
        • Contact:
          • Yannick LE MEUR, MD-PhD
        • Principal Investigator:
          • Yannick LE MEUR, MD-PhD
      • Brest, France, 29200
        • Recruiting
        • AUB Santé foundation, Brest
        • Contact:
          • Morgane GOSSELIN, MD
        • Principal Investigator:
          • Morgane GOSSELIN, MD
      • Chalon-sur-Saône, France
        • Recruiting
        • Department of Nephrology, Hospital of Chalon-sur-Saône
        • Contact:
          • Magali LOUIS, MD
        • Principal Investigator:
          • Magali LOUIS, MD
      • Chartres, France, 28630
        • Recruiting
        • Department of Nephrology, Hospital of Chartres
        • Contact:
          • Nestor NANKEU, MD
        • Principal Investigator:
          • Nestor NANKEU, MD
      • Clermont-Ferrand, France, 63001
        • Recruiting
        • Department of Nephrology, University Hospital of Clermont-Ferrand
        • Contact:
          • Julien ANIORT, MD
        • Principal Investigator:
          • Julien ANIORT, MD
      • Colmar, France, 68024
        • Recruiting
        • Department of Nephrology, Hospital of Colmar
        • Contact:
          • Alexandre KLEIN, MD
        • Principal Investigator:
          • Alexandre KLEIN, MD
      • Grenoble, France, 38043
        • Recruiting
        • Department of Nephrology, University Hospital of Grenoble
        • Contact:
          • Pierre Louis CARRON, MD
        • Principal Investigator:
          • Pierre Louis CARRON, MD
      • Haguenau, France, 67500
        • Recruiting
        • Department of Nephrology, Hospital of Haguenau
        • Contact:
          • Julien OTT, MD
        • Principal Investigator:
          • Julien OTT, MD
      • La Roche-sur-Yon, France, 85925
        • Recruiting
        • Department of Nephrology, Departemental Hospital of Vendée
        • Contact:
          • Anne Hélène QUERARD, MD
        • Principal Investigator:
          • Anne Hélène QUERARD, MD
      • Le Mans, France, 72100
        • Recruiting
        • ECHO Santé Association, Le Mans
        • Contact:
          • Louis Marie VERNIER, MD
        • Principal Investigator:
          • Louis Marie VERNIER, MD
      • Le Puy-en-Velay, France, 43012
        • Recruiting
        • Department of Nephrology, Hospital of Le Puy en Velay
        • Principal Investigator:
          • Marc BOUILLER, MD
        • Contact:
          • Marc BOUILLER, MD
      • Lille, France, 59000
        • Recruiting
        • Department of Nephrology, University Hospital of Lille
        • Contact:
          • Marie FRIMAT, Md-PhD
        • Principal Investigator:
          • Marie FRIMAT, Md-PhD
      • Limoges, France, 87042
        • Recruiting
        • Department of Nephrology, University Hospital of Limoges
        • Contact:
          • Fatouma TOURE, MD-PhD
        • Principal Investigator:
          • Fatima TOURE, MD-PhD
      • Lorient, France, 56100
        • Recruiting
        • AUB Santé foundation, Lorient
        • Contact:
          • Gabrielle DUNEAU, MD
        • Principal Investigator:
          • Gabrielle DUNEAU, MD
      • Lyon, France, 69003
        • Recruiting
        • Department of Nephrology, University Hospital of Lyon
        • Contact:
          • Jean Pierre FAUVEL, MD-PhD
        • Principal Investigator:
          • Jean Pierre FAUVEL, MD-PhD
      • Marseille, France, 13005
        • Recruiting
        • Department of Nephrology, University Hospital of Marseille
        • Contact:
          • Stéphane BURTEY, MD-PhD
        • Principal Investigator:
          • Stéphane BURTEY, MD-PhD
      • Metz, France, 57085
        • Recruiting
        • Department of Nephrology, Regional Hospital of Metz
        • Contact:
          • Thomas QUINAUX, MD
        • Principal Investigator:
          • Thomas QUINAUX, MD
      • Mulhouse, France, 68100
        • Recruiting
        • Department of Nephrology, Régional Hospital of Mulhouse
        • Contact:
          • François CHANTREL, MD
        • Principal Investigator:
          • François CHANTREL, MD
      • Nantes, France, 44093
        • Recruiting
        • Department of Nephrology, University Hospital of Nantes
        • Contact:
          • Caroline GOURRAUD VERCEL, MD
        • Principal Investigator:
          • Caroline GOURRAUD VERCEL, MD
      • Nantes, France, 44402
        • Recruiting
        • ECHO Santé Association, Nantes
        • Contact:
          • Lila GHOUTI TERKI, MD
        • Principal Investigator:
          • Lila GHOUTI TERKI, MD
      • Nîmes, France, 30029
        • Recruiting
        • Department of Nephrology, University Hospital of Nîmes
        • Contact:
          • Olivier MORANNE, MD-PhD
        • Principal Investigator:
          • Olivier MORANNE, MD-PhD
      • Orléans, France, 45067
        • Recruiting
        • Department of Nephrology, Hospital of Orléans
        • Contact:
          • Marion DEKEYSER, MD
        • Principal Investigator:
          • Marion DEKEYSER, MD
      • Paris, France, 75015
        • Active, not recruiting
        • Department of Nephrology, European Hospital Georges Pompidou, AP-HP
      • Paris, France, 75020
        • Active, not recruiting
        • Department of Nephrology, Tenon Hospital, AP-HP
      • Paris, France, 75015
        • Recruiting
        • Department of Nephrology, Necker Hospital, AP-HP
        • Contact:
          • Dominique JOLY, MD-PhD
        • Principal Investigator:
          • Dominique JOLY, MD-PhD
      • Paris, France, 75018
        • Recruiting
        • Department of Nephrology, Bichat Hospital, AP-HP
        • Contact:
          • François VRTOVSNIK, MD-PhD
        • Principal Investigator:
          • François VRTOVSNIK, MD-PhD
      • Perpignan, France, 66046
        • Recruiting
        • Department of Nephrology, Hospital of Perpignan
        • Contact:
          • Sébastien CANET, MD
        • Principal Investigator:
          • Sébastien CANET, MD
      • Reims, France, 51092
        • Recruiting
        • Department of Nephrology, University Hospital of Reims
        • Contact:
          • Pierre Guillaume DELIEGE, MD
        • Principal Investigator:
          • Pierre Guillaume DELIEGE, MD
      • Rennes, France, 35033
        • Recruiting
        • Department of Nephrology, University Hospital of Rennes
        • Contact:
          • Thierry FROUGET, MD
        • Principal Investigator:
          • Thierry FROUGET, MD
      • Roubaix, France, 59100
        • Recruiting
        • Department of Nephrology, Hospital of Roubaix
        • Contact:
          • Thomas GUINCESTRE, MD
        • Principal Investigator:
          • Thomas GUINCESTRE, MD
      • Rouen, France, 76230
        • Recruiting
        • Department of Nephrology, University Hospital of Rouen
        • Contact:
          • Dominique GUERROT, MD-PHD
        • Principal Investigator:
          • Dominique GUERROT, MD-PhD
      • Saint-Etienne, France, 42270
        • Recruiting
        • Department of Nephrology, University Hospital of Saint Etienne
        • Contact:
          • Christophe MARIAT, MD-PhD
        • Principal Investigator:
          • Christophe MARIAT, MD-PhD
      • Saint-Herblain, France, 44819
        • Active, not recruiting
        • ECHO Santé Association, Saint Herblain
      • St-Malo, France, 35400
        • Recruiting
        • Department of Nephrology, Hospital of Saint Malo
        • Contact:
          • Eric RENAUDINEAU, MD
        • Principal Investigator:
          • Eric RENAUDINEAU, MD
      • Strasbourg, France, 67000
        • Recruiting
        • Department of Nephrology, Hospital of Strasbourg
        • Contact:
          • Nans FLORENS, MD-PhD
        • Principal Investigator:
          • Nans FLORENS, MD-PhD
      • Tours, France, 37044
        • Recruiting
        • Department of Nephrology, University Hospital of Tours
        • Contact:
          • Bénédicte SAUTENET, MD
        • Principal Investigator:
          • Bénédicte SAUTENET, MD
      • Valenciennes, France, 59322
        • Recruiting
        • Department of Nephrology, Hospital of Valenciennes
        • Contact:
          • Marc ULRICH, MD
        • Principal Investigator:
          • Marc ULRICH, MD
      • Vandœuvre-lès-Nancy, France, 54511
        • Recruiting
        • Department of Nephrology, University Hospital of Nancy
        • Contact:
          • Adrien FLAHAULT, MD-PhD
        • Principal Investigator:
          • Adrien v, MD-PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male or female >=18 years with a clinical frailty score ≤5 for patient aged over 80
  • Advanced or moderate chronic kidney disease (eGFR 15 to 44.9 mL/min/1.73m² using CKD-EPI formula)
  • Arterial hypertension treated with at least one blood pressure lowering drug therapy among blockers of the renin-angiotensin system (ACEi or ARB), at the maximal posology tolerated by the patients stable since at least one month. Other blood pressure lowering drug therapies are tolerated in combination with or in the event of intolerance to ACE inhibitors or ARBs.
  • Uncontrolled office BP
  • Uncontrolled office BP (>140 and/or 90 mmHg) confirmed by home blood pressure monitoring (>135 and/or 85 mmHg) or Day-time Ambulatory Blood Pressure Monitoring
  • Participant covered by or entitled to social security
  • Written informed consent obtained from the participant

Exclusion Criteria:

  • Patient following any measures of legal presentation
  • Pregnant or breastfeeding woman
  • woman of childbearing without a highly effective contraceptive measure (combined or progestogen-only hormonal contraception associated with inhibition of ovulation, intrauterine device or intrauterine hormone-releasing system)
  • Clinical signs of hypovolemia
  • Symptomatic orthostatic hypotension
  • Hyponatremia (<130 mmol/L)
  • Dyskalemia (<3,5 mmol/L or >5,5 mmol/L)
  • Major adverse cardiovascular event during the last three months: myocardial infarction, heart failure hospitalization, stroke
  • Current medical history of cancer requiring chemotherapy
  • Solid organ transplantation
  • Two or more diuretic agents (loop diuretic, thiazides and thiazide-like diuretics)
  • Mineralocorticoid receptor antagonists
  • Autosomal dominant polycystic kidney disease treated with Tolvaptan
  • Contraindication to diuretics involved in the algorithm
  • Severe heart failure (NYHA III_IV)
  • Cirrhosis Child B-C

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Experimental: Experimental group
Antihypertensive algorithm based on diuretics agents : the clinicians will adjust the drug therapy according to the antihypertensive algorithm based on diuretics agents.
Drug: Antihypertensive algorithm
Antihypertensive algorithm based on diuretics agents
Active Comparator: Control group
Standard of care : the clinicians will adapt the antihypertensive strategy according to his own standard of care which can be pharmacological or non-pharmacological therapies.
Drug: Standard of care
standard of care management for antihypertensive therapy intensification

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
End stage kidney disease
Time Frame: Up to 36 months

The primary endpoint is a time to event outcome, considering the following composite endpoint:

  • End stage kidney disease
  • eGFR decline of at least 40%
  • Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke
  • All cause mortality
Up to 36 months
eGFR decline of at least 40%
Time Frame: Up to 36 months

The primary endpoint is a time to event outcome, considering the following composite endpoint:

  • End stage kidney disease
  • eGFR decline of at least 40%
  • Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke
  • All cause mortality
Up to 36 months
Cardiovascular events
Time Frame: Up to 36 months

The primary endpoint is a time to event outcome, considering the following composite endpoint:

  • End stage kidney disease
  • eGFR decline of at least 40%
  • Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke
  • All cause mortality
Up to 36 months
All cause mortality
Time Frame: Up to 36 months

The primary endpoint is a time to event outcome, considering the following composite endpoint:

  • End stage kidney disease
  • eGFR decline of at least 40%
  • Cardiovascular events among myocardial infarction, heart failure, hospitalization and stroke
  • All cause mortality
Up to 36 months

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Time to end-stage kidney disease
Time Frame: Up to 36 months
All components of the composite endpoint will be assessed separately
Up to 36 months
Time to eGFR decrease of at leat 40%
Time Frame: Up to 36 months
All components of the composite endpoint will be assessed separately
Up to 36 months
Time to the first cardiovascular event among myocardial infarction, heart failure, hospitalization and stroke
Time Frame: Up to 36 months
All components of the composite endpoint will be assessed separately
Up to 36 months
All-cause mortality
Time Frame: Up to 36 months
All components of the composite endpoint will be assessed separately
Up to 36 months
Change from baseline in blood pressure
Time Frame: From baseline and up to 36 months
Systolic and diastolic blood pressure at months 3 and 6 then every 6 months (home blood pressure monitoring and office blood pressure measurement),
From baseline and up to 36 months
Proportion of patients with controlled blood pressure
Time Frame: 24 months
Proportion of patients with controlled blood pressure at 2 years (PA< 135/85mmHg with home blood pressure monitoring)
24 months
Change from baseline in glomerular filtration rate
Time Frame: From baseline and up to 36 months
Change from baseline in glomerular filtration rate estimated by CKD-EPI formula at months 3 and 6 then every 6 months
From baseline and up to 36 months
Proportion of patients who used at least one diuretic
Time Frame: Up to 36 months
Up to 36 months
Change from baseline in quality of life
Time Frame: From baseline and up to 36 months
Change from baseline in quality of life assessed by PROMIS-29 survey each year
From baseline and up to 36 months
Change from baseline in proteinuria (g/d) or proteinuria /creatinuria (g/g)
Time Frame: From baseline and up to 36 months
Change from baseline in proteinuria (g/d) or proteinuria /creatinuria (g/g) at months 3 and 6 then every 6 months
From baseline and up to 36 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
University Hospital, Tours

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: Bénédicte Sautenet, MD, University Hospital, Tours

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
March 28, 2023

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
March 1, 2029

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
March 1, 2029

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
February 8, 2023

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
February 8, 2023

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
February 17, 2023

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
August 3, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
July 31, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • DR210320
  • 2022-501494-39-00 (Other Identifier: EU CT)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Following publication of primary results, deidentified data will be made available from the principal investigator on any reasonable request and based on a methodologically sound proposal. Data dictionaries, study protocol, Statistical Analysis Plan and Informed Consent Form could be shared under the same conditions.

IPD Sharing Time Frame

Following publication of primary results

IPD Sharing Access Criteria

The conditions for the transfer of all or part of the database will be decided by the study sponsor (University Hospital of Tours) and will be the subject of a written contract.

IPD Sharing Supporting Information Type

  • STUDY_PROTOCOL
  • SAP
  • ICF

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings